Mexico Oncology Drugs Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Mexico Oncology Drugs Market Size

• The Mexico Oncology Drugs Market was valued at USD 1.88 billion in 2024 and is expected to reach USD 4.30 billion by 2032, at a CAGR of 10.9% during the forecast period
• This growth is driven by factors such as increasing demand for biologics, advancements in cell line engineering, rising investments in biotechnology research, and expanding applications in gene therapy
• Furthermore, continuous technological advancements in cell line engineering, process optimization, and bioproduction automation are enhancing productivity and product quality. These converging factors are accelerating CHO cell utilization in biologics development, thereby significantly boosting the market’s growth

Mexico Oncology Drugs Market Analysis

• Oncology drugs are pharmaceutical agents specifically designed to prevent, diagnose, or treat various types of cancer by targeting malignant cells while minimizing damage to healthy tissues. These drugs include chemotherapy agents, targeted therapies, immunotherapies, and hormonal treatments that have become essential tools in modern cancer management. Oncology drugs are characterized by their ability to inhibit tumor growth, induce cancer cell death, and improve patient survival outcomes.
• One of the primary focuses of oncology drug development is the creation of targeted and immunotherapeutic agents that can selectively attack cancer cells based on genetic and molecular markers. These advanced therapies are often engineered to enhance efficacy, reduce side effects, and offer more personalized treatment options. The growing understanding of cancer biology and advancements in precision medicine are ensuring improved reliability and effectiveness in cancer care.
• In 2025, the Targeted Drugs segment is expected to dominate the market with a 42.42% market share owing to the rising adoption of molecularly targeted drugs, the growing burden of solid tumors, and an increasing number of approvals for biologics and biosimilars tailored for oncology treatment.

Report Scope and Mexico Oncology Drugs Market Segmentation        

Mexico Oncology Drugs Market Trends

“Growing Integration of Artificial Intelligence (AI) in Oncology Drug Development”

• One prominent trend in the Mexico Oncology Drugs Market is the increasing integration of artificial intelligence (AI) across various stages of oncology drug discovery, clinical trials, and personalized treatment planning.
• AI algorithms are being utilized to analyze vast genomic and clinical datasets, predict drug responses, identify novel therapeutic targets, and optimize treatment regimens with greater precision than traditional research methods.
• For instance, machine learning models can process patient-specific data to predict tumor behavior, treatment efficacy, and potential side effects—significantly reducing the time and cost associated with oncology drug development and clinical decision-making.
• This technology enables faster identification of effective drug candidates, improved accuracy in patient stratification, and enhanced success rates in clinical trials.
• The integration of AI is transforming oncology research and healthcare delivery in Mexico, leading to more efficient drug development, personalized treatment approaches, and a stronger competitive advantage for companies adopting advanced digital and data-driven solutions.

Mexico Oncology Drugs Market Dynamics

Driver

“Rising Use of Artificial Intelligence and Genomic Tools in Oncology Research”

• The rising application of artificial intelligence (AI), genomic profiling, and molecular biology tools in oncology research is emerging as a key driver for the Mexico Oncology Drugs Market. As technologies such as CRISPR-based gene editing, next-generation sequencing (NGS), RNA-seq, and single-cell omics advance, oncology research is shifting from traditional therapeutic development to precision-driven, molecularly targeted innovation. These tools allow researchers to better understand tumor genetics, identify novel biomarkers, and design highly specific therapeutic interventions.
• This shift expands market demand across three interconnected areas: (1) drug discovery—where genomics and AI-driven models accelerate the identification of potential cancer targets and molecules; (2) clinical research and diagnostics—where multi-omics data integration supports personalized treatment selection and resistance prediction; and (3) biomanufacturing and production—where automation and digital-twin technologies enhance biologics production and quality assurance.
• In January 2025, a study published by the National Institutes of Health (NIH) highlighted the growing integration of AI-powered genomic analysis for tumor profiling and drug response prediction, underscoring its role in advancing personalized oncology treatment. Similarly, in April 2025, another NIH article emphasized the importance of integrating transcriptomic and epigenomic data to refine therapeutic targeting strategies in cancer biology.
• The rising use of genomic and AI-based approaches in oncology is not only strengthening the precision and efficiency of cancer drug development but also establishing a foundation for next-generation therapies. This convergence of data science and molecular biology is accelerating innovation, expanding access to advanced treatments, and reinforcing Mexico’s oncology market as a growing hub for precision medicine and biopharmaceutical advancements.

Restraint/Challenge

“High Cost of Oncology Drug Development and Treatment as a Market Restraint”

• The high cost associated with oncology drug development, production, and treatment delivery represents a major restraint on the Mexico Oncology Drugs Market. Developing new cancer therapies—especially biologics, targeted therapies, and immunotherapies—requires substantial investment in research, clinical trials, specialized manufacturing, and regulatory compliance, driving up overall costs for both manufacturers and patients.
• These high costs are further compounded by expensive raw materials, complex production technologies, specialized infrastructure, and the need for skilled professionals in oncology research and clinical care. Moreover, stringent regulatory requirements and long approval timelines add to the financial burden on pharmaceutical companies and delay market entry for innovative treatments.
• As a result, limited affordability and accessibility remain persistent challenges, particularly in lower-income populations and rural areas where access to advanced oncology care is restricted. The high cost of branded cancer drugs can also limit their inclusion in public healthcare programs and restrict availability within the private market.
• For instance, reports from global and regional health authorities have highlighted that oncology biologics and immunotherapies are among the costliest therapeutic categories, significantly contributing to rising healthcare expenditures worldwide. This underscores the financial strain associated with cancer drug development and distribution.
• Despite the growing demand for effective cancer therapies, the capital-intensive nature of oncology drug R&D and production, along with high treatment costs, continues to restrain market growth in Mexico. These financial and infrastructural barriers limit broader adoption and hinder equitable access to advanced cancer care.

Mexico Oncology Drugs Market Scope

The market is segmented on the Drug Class, Drugs Type, Type, Route of Administration, Population Type, Gender, End User, Distribution Channel.

• By Drug Class

On the basis of type, the market is segmented into Cytotoxic drugs, Targeted Drugs, Immunotherapy, and Hormonal Drugs. In 2025, the Targeted Drugs segment is expected to dominate the market with 42.42%, and expected to be fastest growing segment with 11.6% CAGR. the increasing adoption of precision medicine, rising demand for therapies with higher efficacy and lower toxicity, and rapid growth in monoclonal antibodies and tyrosine kinase inhibitors. These therapies are increasingly preferred over conventional cytotoxic drugs, particularly for breast, lung, and hematologic cancers, driving strong market growth.

• By Drugs Type

On the basis of Drugs Type, the market is segmented into Branded, and Generics, In 2025, the Branded segment is expected to dominate the market with 76.12%, and expected to be fastest growing segment with 11% CAGR, the higher adoption of innovative and patented oncology therapies, strong physician preference for clinically proven drugs, extensive marketing and promotional activities by pharmaceutical companies, and greater patient trust in established brands. Additionally, branded drugs often offer advanced formulations, better efficacy, and improved safety profiles compared to generics, which further drives their market share in Mexico’s oncology therapeutics landscape.

• By Type

On the basis of Type, the market is segmented into Breast Cancer, Prostate Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer, Thyroid Cancer, Lung cancer, Blood Cancer, Gastric Cancer, and Others, In 2025, the Breast Cancer segment is expected to dominate the market with 24.85%, and expected to be fastest growing segment with 13.4% CAGR, population, increasing adoption of targeted therapies and immunotherapies for advanced stages, rising awareness about early diagnosis and treatment, and significant investment in research and drug development. The growing use of precision medicine and combination therapy approaches for lung cancer further drives the demand for effective oncology drugs in this segment.

• By Route of Administration

On the basis of Route of Administration, the market is segmented into Oral, Parenteral, In 2025, the Parenteral segment is expected to dominate the market with 65.55%, This dominance is driven by the high utilization of injectable formulations in oncology treatments, particularly for biologics, monoclonal antibodies, and cytotoxic chemotherapies that require precise dosing and rapid systemic action. Parenteral administration ensures better bioavailability and immediate therapeutic response, which is critical for advanced-stage cancers and hospital-based treatments. Moreover, the increasing availability of intravenous infusion therapies and advancements in injectable drug delivery systems further support the dominance of the parenteral segment in Mexico’s Mexico Oncology Drugs Market.

• By Population Type

On the basis of Population Type, the market is segmented into Children, Adults, Geriatric, In 2025, the Adults segment is expected to dominate the market with 82.23%, and Adults expected to be fastest growing segment with 11.1% CAGR. The dominance of the rising incidence of age-related cancers such as lung, prostate, colorectal, and breast cancer among older adults. The growing elderly population in Mexico, coupled with longer life expectancy and increased access to cancer diagnostics and treatments, is driving higher demand for oncology drugs within this age group.

• By Gender

On the basis of Gender, the market is segmented into Male, Female, In 2025, the Female segment is expected to dominate the market with 52.51%, and Female expected to be fastest growing segment with 11.2% CAGR. The dominance the higher prevalence of certain cancers such as prostate, lung, liver, and colorectal cancers among men in Mexico. Lifestyle factors such as higher tobacco and alcohol consumption, occupational exposures, and lower participation in preventive health screenings further contribute to increased cancer incidence in males, driving greater demand for oncology drugs within this segment.

• By End User

On the basis of End User, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers (ASCS), Home Healthcare, and Others, In 2025, the Hospitals segment is expected to dominate the market with 54.57%, and Hospitals expected to be fastest growing segment with 11.0% CAGR. The dominance of the market due to the high volume of cancer diagnoses and treatments conducted in hospital settings, availability of advanced infrastructure for chemotherapy and biologic drug administration, and presence of multidisciplinary oncology teams. Additionally, hospitals serve as primary centers for clinical trials, specialized cancer care, and government-funded treatment programs, further reinforcing their leading position in Mexico’s Mexico Oncology Drugs Market.

• By Distribution Channel

On the basis of Distribution Channel, the market is segmented into Direct Tender, Retail Sales and Others, In 2025, the Retail Sales segment is expected to dominate the market with 68.58%, and Retail Sales expected to be fastest growing segment with 11.0% CAGR. The dominance of the due to large-scale government procurement by public healthcare institutions such as IMSS and ISSSTE. Centralized purchasing ensures cost efficiency, wider access to oncology treatments, and stable drug supply across public hospitals, strengthening the segment’s market share in Mexico.

Mexico Oncology Drugs Market Regional Analysis

• Mexico represents one of the most rapidly expanding oncology drug markets in Latin America, driven by a rising cancer burden, growing awareness about early diagnosis, and improved access to advanced treatment options. The country has witnessed a steady increase in the incidence of cancers such as breast, lung, prostate, colorectal, and cervical cancer, fueling demand for innovative therapies including targeted drugs and immunotherapies.
• The Mexican government, through initiatives under INSABI (Instituto de Salud para el Bienestar), IMSS (Instituto Mexicano del Seguro Social), and ISSSTE (Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado), continues to enhance public access to oncology treatments. These centralized procurement programs under the Direct Tender distribution channel ensure cost efficiency and broaden the reach of essential cancer medicines across public hospitals and healthcare institutions.
• The private healthcare sector in Mexico is also expanding rapidly, supported by the growing presence of specialized oncology centers, an increasing number of clinical trials, and partnerships between multinational pharmaceutical companies and local distributors. This expansion facilitates the introduction of novel biologics, biosimilars, and personalized medicine approaches.
• Despite strong growth prospects, challenges such as high treatment costs, unequal access between urban and rural regions, and complex reimbursement procedures continue to limit patient access to advanced oncology therapies. Nevertheless, ongoing investments in healthcare infrastructure, rising insurance coverage, and the government’s focus on strengthening cancer care delivery are expected to sustain Mexico’s Mexico Oncology Drugs Market growth in the coming years.

The Major Market Leaders Operating in the Market Are:

• AstraZeneca (U.K.)
• Pfizer Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Merck & Co., Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Amgen Inc. (U.S.)
• ARCHIMED (France)
• Astellas Pharma Inc. (Japan)
• Bayer AG (Germany)
• BeOne Medicines (China)
• Boehringer Ingelheim International GmbH (Germany)
• Daiichi Sankyo Company, Limited (Japan)
• Eisai Co., Ltd. (Japan)
• FANASA (Mexico)
• Florencia Healthcare (India)
• Glenmark Pharmaceuticals Ltd. (India)
• Ipsen Pharma (France)
• Johnson & Johnson and its Affiliates (U.S.)
• Knight Therapeutics Inc. (Canada)
• Marzam (Mexico)
• Nadro (Mexico)
• ONCO ESPECIALIZADOS (Mexico)
• PISA (Mexico)
• Probemedic Distribuciones, S.A. de C.V. (Mexico)
• Sanofi (France)

Latest Developments in Mexico Oncology Drugs

• In March 2024, AstraZeneca acquired Fusion Pharmaceuticals (~USD 2 billion) to bolster its oncology pipeline, especially in next‑generation radioconjugates. Fusion’s lead drug candidate, FPI-2265, is a novel radioconjugate designed to treat metastatic castration-resistant prostate cancer (mCRPC), an advanced and difficult-to-treat form of prostate cancer that no longer responds to hormone therapy. Currently in mid-stage clinical trials, FPI-2265 works by delivering targeted radiation directly to prostate cancer cells, potentially improving treatment efficacy while reducing side effects compared to traditional therapies. By acquiring Fusion Pharmaceuticals, AstraZeneca is positioning itself at the forefront of innovative cancer treatments, expanding its capabilities in precision oncology and addressing unmet needs in prostate cancer care.
• In May 2025, AstraZeneca India recently received expanded regulatory approval for its drug Tagrisso (osimertinib) to be used as a monotherapy for patients with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation therapy. This approval is grounded in the positive results of the Phase III LAURA clinical trial, which demonstrated that Tagrisso significantly improves progression-free survival in these patients compared to placebo. Importantly, the trial showed that Tagrisso is effective not only in controlling the cancer in the lungs but also in preventing or delaying disease progression in the central nervous system (CNS), including the brain, which is a common site for metastasis in lung cancer. This expanded indication offers a critical treatment option for patients who have limited choices after initial chemoradiation, helping to improve outcomes and potentially extend survival while maintaining quality of life.
• In February 2025, Pfizer has announced that Jeffrey Legos, PhD, MBA, will join the company as Chief Oncology Officer. Dr. Legos will be responsible for leading Pfizer’s Oncology Research & Development, overseeing all functions from pre-clinical to late-stage clinical development activities. He will report to Chris Boshoff, M.D., PhD, Chief Scientific Officer and President of Pfizer Research & Development, and will represent Oncology on Pfizer’s R&D Leadership Team. Dr. Legos will succeed Roger Dansey, M.D., Interim Chief Oncology Officer, who will transition to retirement.
• In February 2025, Pfizer's ADCETRIS (brentuximab vedotin) combination regimen for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The U.S. FDA has approved. This approval is based on positive data from the Phase 3 ECHELON-3 trial, which demonstrated a significant reduction in the risk of death and a clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo.
• In September 2024, Bristol Myers Squibb (BMS) is set to present data at the European Society for Medical Oncology (ESMO) 2024 conference, showcasing their ongoing leadership in immuno-oncology and the progression of assets from their differentiated research platforms. The presentation will highlight advancements in their immuno-oncology development, including long-term data for Opdivo (nivolumab) and Yervoy (ipilimumab) in metastatic melanoma, as well as promising results from novel modalities and combination therapies in various cancer types. This event underscores BMS's commitment to advancing cancer treatment and improving patient outcomes.

SKU-74954